Your browser doesn't support javascript.
loading
Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
Warmus, Joseph S; Quinn, Cheryl L; Taylor, Clarke; Murphy, Sean T; Johnson, Timothy A; Limberakis, Chris; Ortwine, Daniel; Bronstein, Joel; Pagano, Paul; Knafels, John D; Lightle, Sandra; Mochalkin, Igor; Brideau, Roger; Podoll, Terry.
Afiliação
  • Warmus JS; Department of Chemistry, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. Joseph.Warmus@Pfizer.com
Bioorg Med Chem Lett ; 22(7): 2536-43, 2012 Apr 01.
Article em En | MEDLINE | ID: mdl-22401863
ABSTRACT
Lipid A is an essential component of the Gram negative outer membrane, which protects the bacterium from attack of many antibiotics. The Lipid A biosynthesis pathway is essential for Gram negative bacterial growth and is unique to these bacteria. The first committed step in Lipid A biosynthesis is catalysis by LpxC, a zinc dependent deacetylase. We show the design of an LpxC inhibitor utilizing a robust model which directed efficient design of picomolar inhibitors. Analysis of physiochemical properties drove design to focus on an optimal lipophilicity profile. Further structure based design took advantage of a conserved water network over the active site, and with the optimal lipophilicity profile, led to an improved LpxC inhibitor with in vivo activity against wild type Pseudomonas aeruginosa.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2012 Tipo de documento: Article